Secukinumab in the Treatment of Palmoplantar, Nail, Scalp, and Pustular Psoriasis.
作者信息
Armstrong April W, Vender Ron, Kircik Leon
机构信息
University of Southern California, Los Angeles, California.
Dermatrials Research Inc. and Venderm Innovations in Psoriasis, Hamilton, Ontario, Canada.
出版信息
J Clin Aesthet Dermatol. 2016 Jun;9(6 Suppl 1):S12-S16. Epub 2016 Jun 1.
Abstract
摘要
相似文献
1
Secukinumab in the Treatment of Palmoplantar, Nail, Scalp, and Pustular Psoriasis.
J Clin Aesthet Dermatol. 2016 Jun;9(6 Suppl 1):S12-S16. Epub 2016 Jun 1.
2
The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.
Dermatol Ther (Heidelb). 2017 Dec;7(4):425-446. doi: 10.1007/s13555-017-0207-0. Epub 2017 Nov 15.
3
Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: A 104-week clinical study.
Dermatol Ther. 2019 Sep;32(5):e13006. doi: 10.1111/dth.13006. Epub 2019 Jul 15.
4
Secukinumab is effective in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting.
J Am Acad Dermatol. 2022 Sep;87(3):705-709. doi: 10.1016/j.jaad.2022.05.047. Epub 2022 May 28.
5
Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study.
J Am Acad Dermatol. 2019 May;80(5):1344-1352. doi: 10.1016/j.jaad.2019.01.066. Epub 2019 Feb 1.
6
Rapid response to secukinumab in a 5-year-old with deficiency of the interleukin-36 receptor antagonist (DITRA) with severe scalp and nail involvement.
Pediatr Dermatol. 2021 Sep;38(5):1258-1263. doi: 10.1111/pde.14737. Epub 2021 Aug 2.
7
Similarity and difference between palmoplantar pustulosis and pustular psoriasis.
J Dermatol. 2021 Jun;48(6):750-760. doi: 10.1111/1346-8138.15826. Epub 2021 Mar 2.
8
Recalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab.
JAAD Case Rep. 2018 Sep 19;4(8):842-844. doi: 10.1016/j.jdcr.2018.03.016. eCollection 2018 Sep.
9
Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway.
J Dermatol Sci. 2017 Jan;85(1):20-26. doi: 10.1016/j.jdermsci.2016.09.019. Epub 2016 Sep 29.
10
Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2).
J Drugs Dermatol. 2021 Aug 1;20(8):880-887. doi: 10.36849/JDD.6101.
引用本文的文献
1
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.
Arch Dermatol Res. 2024 Jun 8;316(7):362. doi: 10.1007/s00403-024-03122-w.
2
Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region.
BioDrugs. 2022 Nov;36(6):781-789. doi: 10.1007/s40259-022-00558-2. Epub 2022 Nov 5.
3
Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis.
Dermatol Ther (Heidelb). 2022 Jun;12(6):1289-1302. doi: 10.1007/s13555-022-00746-6. Epub 2022 Jun 7.
4
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
Acta Derm Venereol. 2022 Apr 27;102:adv00698. doi: 10.2340/actadv.v102.563.
5
Real-World Satisfaction with Secukinumab in Clearing the Skin of Patients with Plaque Psoriasis through 24 Months of Follow-Up: Results from US Dermatology Electronic Medical Records.
Dermatol Ther (Heidelb). 2021 Oct;11(5):1733-1749. doi: 10.1007/s13555-021-00599-5. Epub 2021 Aug 28.
6
Toenail Psoriasis during Ustekinumab Therapy: Results and Limitations.
Ann Dermatol. 2021 Apr;33(2):131-137. doi: 10.5021/ad.2021.33.2.131. Epub 2021 Mar 8.
7
Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities.
Dermatol Ther (Heidelb). 2021 Apr;11(2):385-400. doi: 10.1007/s13555-021-00483-2. Epub 2021 Jan 29.
8
Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study.
Acta Derm Venereol. 2021 Mar 31;101(3):adv00422. doi: 10.2340/00015555-3712.
9
IgA vasculitis during secukinumab therapy.
Clin Rheumatol. 2021 May;40(5):2071-2073. doi: 10.1007/s10067-020-05364-1. Epub 2020 Aug 29.
10
Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry.
Dermatology. 2021;237(1):46-55. doi: 10.1159/000504841. Epub 2020 Jan 21.
本文引用的文献
1
Topical treatments for scalp psoriasis.
Cochrane Database Syst Rev. 2016 Feb 26;2(2):CD009687. doi: 10.1002/14651858.CD009687.pub2.
2
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
J Am Acad Dermatol. 2016 Jan;74(1):134-42. doi: 10.1016/j.jaad.2015.09.001.
3
Secukinumab in plaque psoriasis--results of two phase 3 trials.
N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9.
4
Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis.
J Am Acad Dermatol. 2014 Oct;71(4):623-32. doi: 10.1016/j.jaad.2014.04.063. Epub 2014 Jun 2.
5
Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study.
J Eur Acad Dermatol Venereol. 2015 Feb;29(2):353-360. doi: 10.1111/jdv.12553. Epub 2014 May 21.
6
Topical treatments for chronic plaque psoriasis of the scalp: a systematic review.
Br J Dermatol. 2013 Sep;169(3):519-27. doi: 10.1111/bjd.12393.
7
Nail psoriasis - a treatment challenge.
J Dtsch Dermatol Ges. 2013 Mar;11(3):203-19; quiz 220. doi: 10.1111/ddg.12054.
8
Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
Br J Dermatol. 2013 Feb;168(2):402-11. doi: 10.1111/bjd.12112.
9
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.
Br J Dermatol. 2013 Apr;168(4):844-54. doi: 10.1111/bjd.12214.
10
Effect of IL-17A blockade with secukinumab in autoimmune diseases.
Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii116-23. doi: 10.1136/annrheumdis-2012-202371. Epub 2012 Dec 19.
Zotero 插件